Sandra Calvin sold $2.4M of TVTX
SVP, CHIEF ACCOUNTING OFFICER at Travere Therapeutics, Inc.. 67,115 shares at an average of $36.00, traded Nov 4, 2025, filed Nov 6, 2025.
Score components
- +15RoleOfficer
- +25Trade size$2.4M at market
- +20Share of holdings soldSold 58% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +5.1%, 3m -11.5%, 6m +28.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001882909-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 4, 2025 | MOption exercise Common Stock10b5-1 | +10,000 | $25.25 | $253k | 64,410 | Nov 6, 2025 |
| Nov 4, 2025 | MOption exercise Common Stock10b5-1 | +17,500 | $26.88 | $470k | 81,910 | Nov 6, 2025 |
| Nov 4, 2025 | MOption exercise Common Stock10b5-1 | +15,000 | $27.50 | $413k | 96,910 | Nov 6, 2025 |
| Nov 4, 2025 | MOption exercise Common Stock10b5-1 | +12,500 | $22.40 | $280k | 109,410 | Nov 6, 2025 |
| Nov 4, 2025 | MOption exercise Common Stock10b5-1 | +6,250 | $8.93 | $56k | 115,660 | Nov 6, 2025 |
| Nov 4, 2025 | SOpen-market sale Common Stock10b5-1 | -67,115 | $36.00 | $2.4M | 48,545 | Nov 6, 2025 |
| Nov 4, 2025 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 0 | Nov 6, 2025 |
| Nov 4, 2025 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -17,500 | $0.00 | $0 | 0 | Nov 6, 2025 |
| Nov 4, 2025 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 2,500 | Nov 6, 2025 |
| Nov 4, 2025 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -12,500 | $0.00 | $0 | 7,500 | Nov 6, 2025 |
| Nov 4, 2025 | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -6,250 | $0.00 | $0 | 18,750 | Nov 6, 2025 |
Related signals
Other insiders at Travere Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Travere Therapeutics, Inc. | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | $335k 5,375 shares | -11% | |
| 37Weak | Travere Therapeutics, Inc. | Christopher R. Cline CHIEF FINANCIAL OFFICER | $3.1M 50,508 shares | -37% | |
| 50Moderate | Travere Therapeutics, Inc. | Eric M Dube CHIEF EXECUTIVE OFFICER | $25M 400,000 shares | -76% | |
| 40Moderate | Travere Therapeutics, Inc. | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | $18M 283,189 shares | -129% | |
| 30Weak | Travere Therapeutics, Inc. | Jula Inrig EVP, Head of R&D & CMO | $2.8M 44,674 shares | -31% | |
| 30Weak | Travere Therapeutics, Inc. | Elizabeth E Reed Chief Legal Officer and GC | $2.3M 37,500 shares | -26% | |
| 40Moderate | Travere Therapeutics, Inc. | William E. Rote Chief Research Officer | $13M 209,048 shares | -108% | |
| 25Weak | Travere Therapeutics, Inc. | Jeffrey A Meckler director | $1.3M 20,000 shares | -18% | |
| 43Moderate | Travere Therapeutics, Inc. | Christopher R. Cline CHIEF FINANCIAL OFFICER | $43k 642 shares | -1% | |
| 5Weak | Travere Therapeutics, Inc. | Gary A Lyons director | $633k 10,000 shares | -15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.